|
WO9711172A1
|
|
Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
|
|
AU7366296A
|
|
Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
|
|
EP0850066A1
|
|
Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene
|
|
US5955590A
|
|
Conjugates of minor groove DNA binders with antisense oligonucleotides
|
|
AU5259796A
|
|
Delivery of exogenous compounds
|
|
US5772983A
|
|
Methods of screening for compounds which modulate insect behavior
|
|
US5777078A
|
|
Triggered pore-forming agents
|
|
US5612469A
|
|
Enhancement of ribozyme catalytic activity by a neighboring facilitator oligonucleotide
|
|
US5789187A
|
|
Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
|
|
WO9513298A1
|
|
Agrin receptor
|
|
US5559221A
|
|
Method of separating oligonucleotides from a mixture
|
|
WO9425616A1
|
|
Cell-targeted lytic pore-forming agents
|
|
AU3597793A
|
|
Enhancement of ribozyme catalytic activity by a neighboring facilitator oligonucleotide
|
|
CA2126979A1
|
|
Antiparasitic oligonucleotides active against drug resistant malaria
|
|
US5387520A
|
|
Treatment of tumor cells in vitro with neurotrophic factors and cell proliferation inhibitors
|
|
US5652355A
|
|
Hybrid oligonucleotide phosphorothioates
|
|
WO9214845A1
|
|
Diagnosing cystic fibrosis and other genetic diseases using fluorescence resonance energy transfer (fret)
|
|
US5220007A
|
|
Method of site-specific alteration of RNA and production of encoded polypeptides
|
|
US5194428A
|
|
Inhibition of influenza virus replication by oligonucleotide phosphorothioates
|
|
US5149797A
|
|
Method of site-specific alteration of rna and production of encoded polypeptides
|
